|
|
Profile
|
Delegates :
Shin-ichiro Niwa |
|
Incorporated :
August 1 , 2001 |
Paid in Capital :
30 Million yen |
Employees :
10 人 |
Address :
Kamino Bldg.4F 2-1-8 Nihombashi-Horidomecho,Chuo-ku,Tokyo TOKYO
〒103-0012
|
TEL/FAX :
+81-03-5652-0005 / +81-03-5652-1937 |
URL：
http://www.linkgenomics.com |
Attachment :
|
Mission/Background :
A Japanese biotech company,dedicating the fibrosis and antibody drugs for cancer.
Various intractable diseases,such as organ fibrosis,chronic inflammation etc., are caused by the loss of epithelial phenotype in the tissue.
We are focusing on these phenomena as research area and engaged in the drug development based on EMT(Epithelial-Mesenchymal Transition)inhibition. |
|
Technology & Business
|
We have successfully developed a novel cell-based HTS system to find MET inducers and EMT inhibitors which are involved in the fibrosis and related diseases.
We have already obtained several lead compounds for IPF (idiopathic pulmonary fibrosis) .
We already complete the application of the patent at May,2014.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Drug for the treatment for Idiopathic Pulmonary Fibrosis(IPF)
|
Discovery
|
We are developing a new therapeutic drug using existing medicine in a field of IPF that there are no effective therapeutic drugs
|
We are carrying out the evaluation experiment using the model mouse of this disease(BLM) and are obtaining effective results now
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
We already complete the application of the patent at May,2014 and are carrying out the collaborative investigation with the Juntendo University medical department for the purpose of the enforcement of the clinical study now.
|
|
Alliance strategy
|
We are looking for out-licensing and/or co-development partners of our current development pipelines in the world.
|
|
|